Biomotion Sciences Ordinary Shares (SLXN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biomotion Sciences Ordinary Shares (SLXN) has a cash flow conversion efficiency ratio of -12.529x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.65 Million) by net assets ($291.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SLXN equity to assets ratio to measure how much of total assets are equity-financed.
Biomotion Sciences Ordinary Shares - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Biomotion Sciences Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SLXN cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Biomotion Sciences Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomotion Sciences Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NewGenIvf Group Limited Class A Ordinary Shares
NASDAQ:NIVF
|
-0.221x |
|
PDG Realty S.A. Empreendimentos e Participações
SA:PDGR3
|
0.000x |
|
Asian Television Network International Ltd
V:SAT
|
-0.121x |
|
Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
XETRA:EFF
|
0.000x |
|
ENGAGE XR HLDGS EO-001
F:6VR
|
N/A |
|
ODINWELL AB
F:0AF
|
N/A |
|
Europejskie Centrum Odszkodowań SA
WAR:EUC
|
0.002x |
|
Triad Group PLC
LSE:TRD
|
0.245x |
Annual Cash Flow Conversion Efficiency for Biomotion Sciences Ordinary Shares (2020–2025)
The table below shows the annual cash flow conversion efficiency of Biomotion Sciences Ordinary Shares from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see Biomotion Sciences Ordinary Shares (SLXN) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.60 Million | $-10.82 Million | -4.156x | -297.47% |
| 2024-12-31 | $-3.99 Million | $-8.40 Million | 2.105x | +460.29% |
| 2023-12-31 | $-12.06 Million | $-4.53 Million | 0.376x | -20.26% |
| 2022-12-31 | $-7.08 Million | $-3.33 Million | 0.471x | +3946.78% |
| 2021-12-31 | $114.91 Million | $-1.41 Million | -0.012x | -102.78% |
| 2020-12-31 | $-169.99K | $-75.00K | 0.441x | -- |
About Biomotion Sciences Ordinary Shares
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for … Read more